328 related articles for article (PubMed ID: 11967908)
1. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma.
Barnabas N; Amin MB; Pindolia K; Nanavati R; Amin MB; Worsham MJ
J Surg Oncol; 2002 May; 80(1):52-60. PubMed ID: 11967908
[TBL] [Abstract][Full Text] [Related]
2. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
Ma X; Yang K; Lindblad P; Egevad L; Hemminki K
Oncogene; 2001 Aug; 20(38):5393-400. PubMed ID: 11536052
[TBL] [Abstract][Full Text] [Related]
3. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
[TBL] [Abstract][Full Text] [Related]
4. [Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas].
Gong K; Zhang Z; Xin D
Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(3):142-4. PubMed ID: 11798864
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
van Houwelingen KP; van Dijk BA; Hulsbergen-van de Kaa CA; Schouten LJ; Gorissen HJ; Schalken JA; van den Brandt PA; Oosterwijk E
BMC Cancer; 2005 Jun; 5():57. PubMed ID: 15932632
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
9. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
[TBL] [Abstract][Full Text] [Related]
11. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
[TBL] [Abstract][Full Text] [Related]
15. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study.
Hughson MD; Schmidt L; Zbar B; Daugherty S; Meloni AM; Silva FG; Sandberg AA
J Am Soc Nephrol; 1996 Nov; 7(11):2461-8. PubMed ID: 8959640
[TBL] [Abstract][Full Text] [Related]
17. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
[TBL] [Abstract][Full Text] [Related]
18. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
19. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
20. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
Lemm I; Lingott A; Pogge v Strandmann E; Zoidl C; Bulman MP; Hattersley AT; Schulz WA; Ebert T; Ryffel GU
Mol Carcinog; 1999 Apr; 24(4):305-14. PubMed ID: 10326868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
